{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:45:00Z","timestamp":1790023500458,"version":"4.0.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.iac.2020.06.004","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T17:20:38Z","timestamp":1599931238000},"page":"593-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Biologics for Atopic Dermatitis"],"prefix":"10.1016","volume":"40","author":[{"given":"Mark","family":"Boguniewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2020.06.004_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jaci.2014.12.1907","article-title":"Targeted therapy for allergic diseases: at the intersection of cutting-edge science and clinical practice","volume":"135","author":"Boguniewicz","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/jamadermatol.2016.5538","article-title":"Global skin disease morbidity and mortality: An update from the Global Burden of Disease study 2013","volume":"153","author":"Karimkhani","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health","volume":"131","author":"Shaw","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic Dermatitis in America Study: A cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jaci.2019.01.003","article-title":"Report from the National Institute of Allergy and Infectious Diseases workshop on \"Atopic dermatitis and the atopic march: Mechanisms and interventions","volume":"143","author":"Davidson","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","article-title":"Major comorbidities of atopic dermatitis: Beyond allergic disorders","volume":"19","author":"Paller","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune and cardiovascular comorbidities in US adults","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.anai.2019.10.013","article-title":"Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis","volume":"124","author":"He","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamadermatol.2013.10271","article-title":"Persistence of mild to moderate atopic dermatitis","volume":"150","author":"Margolis","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib13","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?","volume":"139","author":"Bieber","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation","volume":"242","author":"Boguniewicz","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.iac.2020.06.004_bib15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jaad.2019.04.036","article-title":"The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease","volume":"81","author":"Brunner","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2015.01.020","article-title":"Severe atopic dermatitis is characterized by selective expansion of circulating TH2\/TC2 and TH22\/TC22, but not TH17\/TC17, cells within the skin-homing T-cell population","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib19","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","article-title":"Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype","volume":"138","author":"Simpson","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.004_bib20","doi-asserted-by":"crossref","first-page":"e98006","DOI":"10.1172\/jci.insight.98006","article-title":"Lipid abnormalities in atopic skin are driven by type 2 cytokines","volume":"3","author":"Berdyshev","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.iac.2020.06.004_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","article-title":"Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2020.06.004_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? recommendations from an expert panel of the international eczema council","volume":"77","author":"Simpson","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic Dermatitis Yardstick: Practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaip.2018.10.021","article-title":"Strategies for successful management of severe atopic dermatitis","volume":"7","author":"Brar","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2020.06.004_bib25","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1172\/JCI116240","article-title":"Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T\u00a0cells by staphylococcal toxin superantigens","volume":"91","author":"Takei","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.iac.2020.06.004_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0190-9622(99)70544-X","article-title":"Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis","volume":"40","author":"Jolles","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0002-9343(90)90490-5","article-title":"Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels","volume":"88","author":"Boguniewicz","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.iac.2020.06.004_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0190-9622(93)70026-P","article-title":"Recombinant interferon gamma therapy for atopic dermatitis","volume":"28","author":"Hanifin","year":"1993","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1081-1206(10)62968-7","article-title":"Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis","volume":"80","author":"Schneider","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archderm.134.7.799","article-title":"Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels","volume":"134","author":"Stevens","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archderm.134.7.870","article-title":"Atopic dermatitis: a question of balance","volume":"134","author":"Boguniewicz","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1525-1470.2010.01356.x","article-title":"The clinical spectrum and therapeutic challenge of eczema herpeticum","volume":"28","author":"Frisch","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.iac.2020.06.004_bib35","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/all.14050","article-title":"Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis","volume":"75","author":"Kang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2020.06.004_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab) treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib37","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jaci.2008.03.007","article-title":"Anti-CD20 (rituximab) treatment for atopic eczema","volume":"121","author":"Sediv\u00e1","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib38","first-page":"190","article-title":"Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis","volume":"23","author":"S\u00e1nchez-Ram\u00f3n","year":"2013","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib39","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt.15.69","article-title":"Drug evaluation review: dupilumab in atopic dermatitis","volume":"7","author":"Hamilton","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.iac.2020.06.004_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib41","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2020.06.004_bib42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.17791","article-title":"Dupilumab provides important clinical benefits to patient with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib43","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2020.06.004_bib44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib47","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaad.2018.07.048","article-title":"Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"80","author":"Blauvelt","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","article-title":"IL-4R\u03b1 blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis","volume":"140","author":"Callewaert","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.004_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Simpson","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40257-019-00478-y","article-title":"Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial","volume":"21","author":"Paller","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/pde.13697","article-title":"Long-term off-label dupilumab in pediatric atopic dermatitis: a case series","volume":"36","author":"Treister","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/pde.13707","article-title":"Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis","volume":"36","author":"Siegfried","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib55","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaad.2013.05.035","article-title":"Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective","volume":"69","author":"Lacombe Barrios","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib56","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","article-title":"Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis","volume":"138","author":"Wang","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.06.004_bib57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial","volume":"174","author":"Chan","year":"2019","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.iac.2020.06.004_bib58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2020.06.004_bib59","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib61","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ra1 and IL-13Ra2","volume":"429","author":"Popovic","year":"2017","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.iac.2020.06.004_bib62","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2020.06.004_bib63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: A phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.iac.2020.06.004_bib64","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2020.06.004_bib65","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaci.2005.10.046","article-title":"IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T\u00a0cells in patients with atopic dermatitis","volume":"117","author":"Bilsborough","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdermsci.2014.02.009","article-title":"Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis","volume":"74","author":"Kato","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.iac.2020.06.004_bib67","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2020.06.004_bib68","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib70","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"Stander","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2020.06.004_bib71","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"515","key":"10.1016\/j.iac.2020.06.004_bib72","doi-asserted-by":"crossref","first-page":"eaax2945","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.iac.2020.06.004_bib73","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib74","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2020.06.004_bib75","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2020.06.004_bib76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856120300394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856120300394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:44:14Z","timestamp":1760179454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856120300394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0889856120300394"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2020.06.004","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2020.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}